Literature DB >> 18319310

Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes.

Ayad A Jaffa1, William R Usinger, M Brent McHenry, Miran A Jaffa, Stuart R Lipstiz, Daniel Lackland, Maria Lopes-Virella, Louis M Luttrell, Peter W F Wilson.   

Abstract

OBJECTIVE: We explored the relevance and significance of connective tissue growth factor (CTGF) as a determinant of renal and vascular complications among type 1 diabetic patients. METHODS AND
RESULTS: We measured the circulating and urinary levels of CTGF and CTGF N fragment in 1050 subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study cohort. We found that hypertensive diabetic subjects have significantly higher levels of plasma log CTGF N fragment relative to normotensive subjects (P = 0.0005). Multiple regression analysis showed a positive and independent association between CTGF N fragment levels and log albumin excretion rate (P < 0.0001). In categorical analysis, patients with macroalbuminuria had higher levels of CTGF N fragment than diabetic subjects with or without microalbuminuria (P < 0.0001). Univariate and multiple regression analyses demonstrated an independent and significant association of log CTGF N fragment with the common and internal carotid intima-media thickness. The relative risk for increased carotid intima-media thickness was higher in patients with concomitantly elevated plasma CTGF N fragment and macroalbuminuria relative to patients with normal plasma CTGF N fragment and normal albuminuria (relative risk = 4.76; 95% confidence interval, 2.21-10.25; P < 0.0001).
CONCLUSION: These findings demonstrate that plasma CTGF is a risk marker of diabetic renal and vascular disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319310      PMCID: PMC2386274          DOI: 10.1210/jc.2007-2544

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  The modular architecture of a new family of growth regulators related to connective tissue growth factor.

Authors:  P Bork
Journal:  FEBS Lett       Date:  1993-07-26       Impact factor: 4.124

2.  Expression of connective tissue growth factor in human renal fibrosis.

Authors:  Y Ito; J Aten; R J Bende; B S Oemar; T J Rabelink; J J Weening; R Goldschmeding
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

3.  Mechanisms of low-density lipoprotein-induced expression of connective tissue growth factor in human aortic endothelial cells.

Authors:  Mimi Sohn; Yan Tan; Bing Wang; Richard L Klein; Maria Trojanowska; Ayad A Jaffa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-04       Impact factor: 4.733

4.  Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation?

Authors:  Vincent Rigalleau; Catherine Lasseur; Caroline Perlemoine; Nicole Barthe; C Raffaitin; Chung Liu; Phillipe Chauveau; Laurence Baillet-Blanco; Marie-Christine Beauvieux; C Combe; Henri Gin
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

5.  Human connective tissue growth factor is expressed in advanced atherosclerotic lesions.

Authors:  B S Oemar; A Werner; J M Garnier; D D Do; N Godoy; M Nauck; W März; J Rupp; M Pech; T F Lüscher
Journal:  Circulation       Date:  1997-02-18       Impact factor: 29.690

6.  Evidence for low-density lipoprotein-induced expression of connective tissue growth factor in mesangial cells.

Authors:  Mimi Sohn; Yan Tan; Richard L Klein; Ayad A Jaffa
Journal:  Kidney Int       Date:  2005-04       Impact factor: 10.612

7.  Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice.

Authors:  Bryan A Game; Lin He; Veronica Jarido; Alena Nareika; Ayad A Jaffa; Maria F Lopes-Virella; Yan Huang
Journal:  Atherosclerosis       Date:  2006-08-09       Impact factor: 5.162

8.  Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells.

Authors:  M Murphy; C Godson; S Cannon; S Kato; H S Mackenzie; F Martin; H R Brady
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

9.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

10.  Intrinsic biological activity of the thrombospondin structural homology repeat in connective tissue growth factor.

Authors:  Zhen-Yue Tong; David R Brigstock
Journal:  J Endocrinol       Date:  2006-03       Impact factor: 4.286

View more
  26 in total

Review 1.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

Review 2.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

3.  Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells.

Authors:  Hesham M El-Shewy; Mimi Sohn; Parker Wilson; Mi Hye Lee; Samar M Hammad; Louis M Luttrell; Ayad A Jaffa
Journal:  Mol Endocrinol       Date:  2012-03-15

4.  Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes.

Authors:  Bing Wang; Rickey E Carter; Miran A Jaffa; Sashidhar Nakerakanti; Daniel Lackland; Maria Lopes-Virella; Maria Trojanowska; Louis M Luttrell; Ayad A Jaffa
Journal:  J Med Genet       Date:  2010-06       Impact factor: 6.318

5.  Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.

Authors:  Sharon G Adler; Sherwyn Schwartz; Mark E Williams; Carlos Arauz-Pacheco; Warren K Bolton; Tyson Lee; Dongxia Li; Thomas B Neff; Pedro R Urquilla; K Lea Sewell
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

6.  Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease.

Authors:  Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2010-10-19       Impact factor: 5.782

7.  Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.

Authors:  William Brian Reeves; Bishal B Rawal; Emaad M Abdel-Rahman; Alaa S Awad
Journal:  Open J Nephrol       Date:  2012-06-25

Review 8.  Chronic kidney disease prediction is an inexact science: The concept of "progressors" and "nonprogressors".

Authors:  Macaulay Amechi Chukwukadibia Onuigbo; Nneoma Agbasi
Journal:  World J Nephrol       Date:  2014-08-06

9.  Effects of vitamin D on renal fibrosis in diabetic nephropathy model rats.

Authors:  Yanyan Tian; Guodong Lv; Ye Yang; Yuanyuan Zhang; Rui Yu; Jia Zhu; Lati Xiao; Jun Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

10.  CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB.

Authors:  Elsa Sánchez-López; Sandra Rayego; Raquel Rodrigues-Díez; Javier Sánchez Rodriguez; Raúl Rodrigues-Díez; Juan Rodríguez-Vita; Gisselle Carvajal; Luiz Stark Aroeira; Rafael Selgas; Sergio A Mezzano; Alberto Ortiz; Jesús Egido; Marta Ruiz-Ortega
Journal:  J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.